| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 3.04 | 2.0% |
| Total Income | 3.04 | 2.0% |
| Expenditure | 61.46 | 14.5% |
| PBT | -48.44 | 22.5% |
| Net Profit | -48.44 | 22.5% |
| OPM | — | |
| NPM | — | |
| EPS | -0.40 | 17.6% |
NewAmsterdam Pharma Reports Q1 2026 Results; Cash Position at $707.3 Million
07 May 2026 · 7 May, 4:37 pm
Summary
NewAmsterdam Pharma announced its financial results for the quarter ended March 31, 2026. The company's cash position was reported at $707.3 million. Revenue remained consistent at $3.0 million compared to the same period last year. R&D expenses decreased to $38.0 million, while SG&A expenses also saw a decrease to $23.5 million. The net loss for the quarter was $48.4 million, increasing from $39.5 million in the prior year.
Key Highlights
- 1
NewAmsterdam Pharma reported a cash position of $707.3 million as of March 31, 2026.
- 2
The company recognized $3.0 million in revenue for the quarter ended March 31, 2026, consistent with the same period in 2025.
- 3
Research and Development expenses were $38.0 million for the quarter ended March 31, 2026, compared to $44.8 million for the same period in 2025.
- 4
Selling, General and Administrative expenses were $23.5 million for the quarter ended March 31, 2026, compared to $27.2 million for the same period in 2025.
- 5
Net loss for the quarter ended March 31, 2026, was $48.4 million, compared to a net loss of $39.5 million for the same period in 2025.
- 6
The company expects decisions on regulatory approval from EMA, UK, and Switzerland for obicetrapib and obicetrapib/ezetimibe fixed‑dose combination in 2H26.
- 7
PREVAIL interim analysis is planned for 4Q2026 with results expected in 1Q2027.
Management Comments
Michael Davidson
M.D.
“Our clinical execution remains strong. We have completed enrollment in REMBRANDT and continue to advance PREVAIL and RUBENS — three Phase 3 trials that underscore the breadth and maturity of our development program. We are excited following an initial blinded review of PREVAIL data after the two-year anniversary of enrollment completion — which showed a Year 1 overall MACE event rate consistent with BROADWAY and a Year 1-to-Year 2 overall MACE event rate lower than expected — and we have decided to conduct an interim analysis in the fourth quarter of 2026. This timing coincides with the minimum 2.5-year follow-up for the trial. We are optimistic about the interim analysis and expect to report the result of the analysis in the first quarter of 2027. Should the trial not stop for efficacy at that time, we anticipate completion by the end of 2027. We will provide further details at our annual Investor Day on August 5, 2026.”
Informational and educational content only. Not investment advice.